Jan'05 | Jan'06 | Jan'07 | Jan'08 | Jan'09 | Jan'10 | Jan'11 | Jan'12 | Jan'13 | Jan'14 | Jan'15 | Jan'16 | Jan'17 | Jan'18 | Jan'19 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Return on Equity (ROE) | (4.0%) | (12.9%) | (27.1%) | (49.7%) | (105.7%) | (53.2%) | (98.5%) | (98.2%) | (174.2%) | (178.9%) | (125.5%) | (109.0%) | (249.8%) | (320.8%) | 18.9% | (40.9%) | (75.0%) | (108.9%) | (75.1%) | (601.8%) |
Discover the top 20 best undervalued stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Jan 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Jan 2025.
As of today, Microsoft Corp's last 12-month Return on Equity (ROE) is (62.1%), based on the financial report for Sep 30, 2024 (Q3 2024). The average annual Return on Equity (ROE) for Summit Therapeutics Inc. have been (221.2%) over the past three years, and (189.5%) over the past five years.
As of today, Summit Therapeutics Inc.'s Return on Equity (ROE) is (62.1%), which is lower than industry median of (52.7%). It indicates that Summit Therapeutics Inc.'s Return on Equity (ROE) is Bad.